The Torpedo nicotinic acetylcholine receptor (nAChR) 1 is made up of four homologous, transmembrane subunits (␣ 2 ␤␥␦) that associate pseudosymmetrically about a central axis that forms the cation-selective ion channel. Efficient channel gating depends upon the binding of two acetylcholine (ACh) molecules.
The binding sites for agonist and competitive antagonists are within the extracellular domain of the nAChR at the ␣-␥ and ␣-␦ subunit interfaces (1) (2) (3) . Affinity labeling and mutagenesis studies support a model for agonist site structure with contributing amino acids from three distinct regions of the ␣-subunits and from multiple regions of the ␥ (or ␦)-subunit (reviewed in Refs. 4 -6) . For Torpedo nAChR, photoaffinity labeling with the competitive antagonist p- [ 3 H]dimethylaminobenzenediazonium fluoroborate identified residues in three distinct regions of the ␣-subunit primary sequence: ␣Tyr 93 (loop A), ␣Trp
149
(loop B), and ␣Tyr 190 (loop C) (7, 8 (9 -11) . Using a heterobifunctional cross-linker ϳ9 Å in length, ␣Cys 192/193 was cross-linked to a negatively charged residue in the ␦-subunit identified as ␦Asp 180 (loop F) (12) . In embryonic mouse muscle nAChR (␣ 2 ␤␥␦), the site selectivity of dimethyl-d-tubocurarine has been attributed to amino acid differences in loop E (␥Ile 116 Tyr 117 /␦Val 118 Thr 119 ) and loop F (␥Ser 161 /␦Lys 163 ) (13, 14) , while for adult mouse nAChR (␣ 2 ␤⑀␦) antagonist affinity determinants have been identified in loop D (␥Glu 57 ) and other regions of non-␣ subunit (15) .
Despite the availability of this large body of information about the identity of amino acids that contribute to the agonist binding site, little is known about their overall three-dimensional distribution or about the orientation of agonists or antagonists bound within the site. ACh has two functional groups, the acetyl group and a quaternary ammonium group located within 6.4 Å of the carbonyl carbon. Simpler quaternary ammonium compounds including choline and tetramethylammonium also act as agonists, although they are less potent than ACh, and when bound the probability of channel opening is substantially lower than for ACh (16, 17) . While 4-(N-maleimido)benzyltrimethylammonium (MBTA) acts as an irreversible antagonist after reaction with ␣Cys 192/193 in reduced, wild type nAChR (18) , bromoacetylcholine (BrACh) acts as a covalent agonist after reaction with ␣Cys 192/193 (19, 20) . Thus, in the reduced nAChR, interactions of the trimethylammonio group within 9 Å of ␣Cys 192/193 are sufficient for channel gating. Affinity labeling with [ 3 H]ACh mustard, containing the positive charge within a reactive aziridinium, indicates that the positive charge of ACh interacts with ␣Tyr 93 in the desensitized state of the nAChR (21) . Replacement of ␣Trp 149 by an unnatural amino acid, Tyr-O-(CH 2 ) 3 N(CH 3 ) 3 , results in a constitutively active receptor (22) , suggesting that an interaction between the quaternary ammonium ion and the ␣149 side chain may be important for nAChR activation.
To further characterize the agonist binding site structure, we have introduced Cys substitutions in ␣-subunit in ACh site loops A, B, and C and in ␥-subunit loop D and examined the functional properties of these mutant nAChRs after reaction with sulfhydryl reagents. Cys mutagenesis has been widely used to determine secondary structure in a number of ion channels and membrane topology, residue accessibility, and transmembrane proximity of several bacterial membrane proteins (23, 24) . In studies of nAChR, it has been used to study the structure of the ion channel (25) (26) (27) and to identify residues in binding site loops C and E important for ␣-neurotoxin binding (28 -30) . We describe here studies of Torpedo nAChR wild type and Cys mutant subunits expressed in Xenopus oocytes and assayed by monitoring ACh-elicited currents in the twoelectrode voltage clamp configuration and by measuring surface receptor levels by 125 I-␣-bungarotoxin (␣-BgTx) binding. The effects of covalent modification within the binding site were investigated using sulfhydryl-specific reagents, including MBTA, BrACh, and methanethiosulfonate (MTS) derivatives, which can add to Cys-SH a variety of differently charged and sized groups (31). 2-Aminoethylmethanethiosulfonate (MTSEA) adds a positively charged primary amine to Cys. [2-(Trimethylammonium)ethyl]methanethiosulfonate (MTSET) covalently attaches thiocholine to Cys. [1-(Trimethylammonium)methyl]-methanethiosulfonate (MTSMT), which is one methylene shorter than MTSET, adds a thio(trimethylamino)methyl group to Cys, and [1-(trimethylammonium) propyl]methanethiosulfonate (MTSPT), which is one methylene longer than MTSET, ads homo-thiocholine. The results presented here begin to define the orientation of the quaternary ammonium ion within the agonist binding site that is required for nAChR activation.
EXPERIMENTAL PROCEDURES
cDNA Mutagenesis-pSP64-based plasmids (pMXT) containing cDNAs encoding the wild type ␣-, ␥-, and ␦-subunits were gifts from Dr. Michael White (Departments of Pharmacology and Physiology, MCP Hahnemann University, Philadelphia, PA), and the ␤-subunit cDNA in pSP64 was from Dr. Henry Lester (California Institute of Technology, Pasadena, CA). Mutants were constructed using "overlap extension" PCR, which consists of two successive PCRs (32) . Primers used for PCR and DNA sequencing were purchased from Life Technologies, Inc. DNA modifying enzymes were purchased from New England Biolabs (Beverly, MA) and Life Technologies, Inc. Qiagen (Valencia, CA) Minipreps were used to propagate plasmid DNAs. All PCRs were performed using Pfu polymerase (Stratagene, La Jolla, CA). Mutagenic primers were generally 30 -40 base pairs long, and the mismatch region was surrounded by at least 12 base pairs on each side. The overlap region for the first and second PCR products was 12-20 base pairs. Mutations around ␣Tyr 93 were made by generating an ϳ300-base pair PCR product that was subcloned using unique restriction sites within the ␣-subunit coding region: Bsu36I and BsiWI. Mutations at ␣Trp 149 were generated using conventional one-step PCR mutagenesis by incorporating the desired change into the antisense primer, which overlapped at the BsiWI site, and using the sense primer, which overlapped the Bsu36I site. Mutations in the ␣-subunit at ␣Tyr 190 and ␣Tyr 198 were generated using primers that gave ϳ1000-base pair PCR product, which could be subcloned using the Bsu36I restriction site and the BbvII site near the 3Ј end of the coding region. Mutations around ␥Trp 55 were made by generating an ϳ1.13-kilobase PCR product that was subcloned using the unique HindIII site in the vector and the StuI site in the ␥-subunit coding region. Each PCR mix contained 0.5 M primers, 50 ng of template DNA, and 0.4 mM dNTPs in the reaction buffer supplied with the enzyme. For ␣Tyr 93 mutations, the first PCR reactions were for 30 cycles with a three-step protocol (2 min at 94°C, 1 min at 50°C, 1 min at 72°C); the second PCR reactions were for 24 cycles (1.5 min at 95°C, at 45°C, and at 72°C). The latter 24-cycle protocol was also used for both PCR reactions for mutations at ␣Tyr 190 and ␣Tyr 198 and also for mutations around ␥Trp 55 . The desired PCR products were purified from excised agarose gel slices using cellulose acetate centrifugal filters (Costar, Corning, NY) or by traditional phenol extraction/ethanol precipitation. The final PCR product containing the desired mutation was inserted into the subunit gene using DNA ligase (Life Technologies, Inc.). Incorporation of the engineered mutation and the fidelity of the PCR were confirmed by DNA sequencing (Biopolymers Facilities, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA) through the amplified region. 
In Vitro Transcription and Expression in Xenopus Oocytes
, where I and I max are the currents at a given concentration of ACh and the maximal current, respectively. K app is the apparent activation constant for ACh, and n is the Hill coefficient. pCLAMP (Axon Instruments, Foster City, CA) and SigmaPlot (SPSS Inc., Chicago, IL) software were used for data analysis.
Rate Constants of nAChR Modification-For the Cys reagents producing irreversible inhibition of ACh responses, the time course of the reaction with a substituted Cys mutant in the absence of ACh was determined by recording the initial response to ACh and then the response to ACh after repeated applications of modifying reagent for 5-s intervals. Each application of reagent was followed by a ϳ1-min wash, three ACh test applications (5 s each), and a 1-min wash. ACh was generally applied at a concentration equal to K app . ACh-induced currents after treatment were plotted as a function of cumulative modification time (t) and fit by a single exponential function, I t ϭ I o exp(Ϫkxt) where x is the concentration of the reagent and k the second order rate constant (33) . At least two concentrations of reagent were tested on two separate days. For reagents resulting in irreversible activation of nAChRs, responses were measured after each 5-s application, and ACh test pulses were omitted. Observed currents were fit to the function:
Surface nAChR Labeling-To measure binding to nAChRs expressed on the surface, oocytes were incubated with 2.5 nM 125 I-␣-BgTx (2000 Ci/mmol) (Amersham Pharmacia Biotech) for 2 h at room temperature in a final volume of 200 l of ND96 ϩ 0.1% bovine serum albumin and then washed three times with 500 l of ND96. Oocytes were transferred to individual tubes and counted for 5 min/tube in a ␥ counter. To determine whether the introduction of Cys at any of these positions disrupted nAChR expression, we assessed functional properties by measuring ACh-elicited currents and the binding of 125 I-␣-BgTx to nAChRs on the oocyte surface. Most of the Cys substitutions were well tolerated, when expressed with other wild type subunits ( Fig. 1 ). Under our experimental conditions, for wild type nAChR, the K app for ACh was 25 M with a Hill coefficient of 1.6 and injection of 10 ng of subunit RNA resulted in the expression on the oocyte surface of ϳ4 fmol of 125 I-␣-BgTx binding 48 h after injection. The Cys substitutions in ␥-subunit at ␥Trp 55 (K app ϭ 31 M, n H ϭ 1.6) and ␥Glu 57 (K app ϭ 54 M, n H ϭ 1.7) caused little if any shift of K app or Hill coefficient, as compared with wild type, and the maximal currents and sur-face 125 I-␣-BgTx binding were also similar to wild type. Cys substitutions at ␣Tyr 93 (K app ϭ 520 M, n H ϭ 1.9) and ␣Tyr
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(K app ϭ 790 M, n H ϭ 1.4) caused substantial shifts of K app , consistent with previous mutational studies, where more conservative substitutions at these positions also resulted in significant decreases in ACh potency (34, 35) . For these mutant receptors, surface 125 I-␣-BgTx binding was ϳ50% of wild type, but the maximal currents were only ϳ1% of wild type. Oocytes expressing ␣Y190C nAChRs showed no ACh-elicited current and had low surface receptor levels (Ͻ10% of wild type), as reported for the same mutation in the mouse muscle nAChR (28) . Oocytes expressing ␣W149C nAChRs also showed no ACh-elicited currents, although their surface receptor levels were similar to those of ␣Y93C and ␣Y198C nAChRs. The I max and surface receptor measurements showed that Cys substitutions at ␣Tyr 93 , ␣Tyr 198 , ␥Trp 55 , and ␥Glu 57 resulted in functional receptors expressed at levels sufficient for further analysis.
Modification of Cys Mutants by MBTA and MTSEA-Oocytes expressing wild type nAChR or mutant nAChRs containing agonist site cysteines were reacted with MBTA or MTSEA in the absence of agonist and then retested for sensitivity to ACh. MBTA, a sulfhydryl-reactive benzyltrimethylammonium, is known to act as an irreversible antagonist of wild type nAChR after reduction of the ␣Cys 192/193 disulfide (18), and we reasoned that if it reacted with cysteines introduced at other positions in the active site it might also act as an irreversible antagonist. Reaction with MTSEA would introduce a positively charged primary amine within the binding site. The general protocol was to first measure the response to ACh at a concentration close to its K app , then expose the oocyte to MBTA (1 mM) or MTSEA (2 mM) for 5 s, and then to remeasure the ACh response after a 1-2-min wash to remove reversibly bound reagent (Fig. 2) . Representative current traces are shown for wild type nAChRs and for ␣Y93C and ␣Y198C mutant nAChRs treated with MBTA ( Fig. 2A) and MTSEA (Fig. 2B) , as well as summary data for those mutants as well as the ␥W55C and 
. B, maximal current response, I max , was determined using concentrations of ACh determined from dose-response curves; for wild type, ␥W55C, and ␥E57C 300 M ACh was used, and for ␣Y93C and ␣Y198C 3 mM ACh was used. Wild type and ␥ mutant oocytes were injected with 0.5 ng of RNA (striped bars) and ␣ mutant oocytes were injected with 10 ng of RNA (white bars); each bar represents the mean I max Ϯ S.D. from at least three oocytes. Surface receptor (black bars) levels were determined by measuring 125 I-␣-BgTx binding as described under "Experimental Procedures." All oocytes were injected with 10 ng of RNA for the surface receptor binding assay. Each bar represents the mean surface receptor level Ϯ S.D. for 7 oocytes. ␥E57C mutants (Fig. 2C) . For oocytes expressing wild type nAChR, after treatment with MBTA and washing, there was a small (ϳ20%) decrease in the response to ACh, substantially less than the 75% and 95% inhibition seen for ␣Y93C and ␣Y198C nAChRs, respectively. For wild type nAChR, exposure to MTSEA resulted in no irreversible inhibition, while there was Ͼ95% inhibition of ACh responses for ␣Y93C and ␣Y198C mutant nAChRs. For Cys substitution within loop D of ␥-subunit, treatment of ␥E57C nAChRs with either MBTA or MT-SEA resulted in irreversible current inhibition, while treatment of ␥W55C nAChRs resulted in no inhibition greater than that seen for wild type nAChRs. Even after treatment of ␥W55C nAChRs with 5 mM MTSEA for 4 min, after washing the ACh response was inhibited by Ͻ10% (data not shown). These results established that ␥E57C, ␣Y93C, and ␣Y198C were accessible for chemical modification and that reaction at those positions with either MBTA or MTSEA resulted in the addition of covalent antagonists. The lack of effect at ␥W55C indicates that Cys at that position is not accessible for chemical modification.
The ACh responses of ␥E57C, ␣Y93C, and ␣Y198C nAChRs were significantly affected by MTSEA treatment. To further characterize this inhibition, we determined the full ACh doseresponse curves before and after a 5-s treatment of MTSEA (Fig. 3A) . Consistent with irreversible inactivation of nAChRs, MTSEA treatment caused a decrease in the peak current response for each of the mutant nAChRs with little if any shift in the K app .
Modification of Cys Mutants by MTSET-
The effects of the addition of thiocholine to agonist site cysteines were studied by reacting mutant nAChRs with MTSET (Fig. 4) . MTSET at 100 M neither acted as an agonist for wild type nAChR nor produced irreversible inhibition of ACh responses. The same MT-SET treatment resulted in a complete, irreversible inhibition of ␣Y93C nAChRs and a partial inhibition of ␥E57C nAChR responses. The modifications resulted in decreased maximal currents for ACh without alteration of K app (Fig. 3B) . As for MBTA and MTSEA, for ␥W55C nAChRs, exposure to 5 mM MTSET for as long as 4 min led to Ͻ10% reduction of the ACh response, an extent of inhibition similar to that seen for wild type nAChR (data not shown).
MTSET treatment of ␣Y198C nAChRs produced a very different result. Treatment of oocytes expressing ␣Y198C nAChRs with 10 M MTSET resulted in the onset of a large, inward current, which was sustained upon MTSET washout (Fig. 4A) . In comparison with the response to ACh (at K app ) seen before treatment with MTSET, the peak current observed after treatment with MTSET was actually 7 times as large. MTSET treatment of oocytes injected with ␣Y190C or ␣W149C nAChRs did not produce any measurable currents (data not shown). While thiocholine tethered at positions ␣Y93C or ␥E57C acted as a covalent antagonist, it appeared to act as a covalent agonist when tethered at position ␣Y198C.
Pharmacological Profile of MTSET Reaction with ␣Y198C nAChRs-To test whether MTSET was acting through the agonist binding site, we examined whether binding of the competitive antagonist, dTC, would prevent reaction of MTSET with the ␣Y198C nAChR (Fig. 5) . As expected, when dTC at 10 M was coapplied with ACh, there was a reversible inhibition of ACh response. When coapplied with 1 M MTSET, 10 M dTC prevented the reaction of MTSET with ␣Y198C, as evidenced by the lack of conductance response. Upon washing, there was no detectable inward current, but subsequent re-exposure to 1 M MTSET produced an inward current that gradually declined during minutes of washing. When ACh was applied after several minutes of washing, it reversibly inhibited the sustained current, presumably because at a holding potential of Ϫ70 mV, 1 mM ACh acts as an open channel blocker (36) . The inward current seen after treatment with MTSET decreased slowly, typically by 50% in 1 min, and treatment of the oocyte with 1 mM dithiothreitol produced a more rapid return to base line, after which ACh once again elicited inward currents (data not shown). Further studies would be required to determine whether the gradual decrease of the inward current reflected slow desensitization of the mutant nAChR and/or whether persistent channel gating at Ϫ70 mV resulted in a gradual increase of sodium concentration within the oocyte.
The sustained, inward current seen after reaction of ␣Y198C nAChRs with MTSET was inhibitable by nAChR aromatic amine noncompetitive antagonists (Fig. 6) . The classic nAChR open channel blocker QX-222 (37) produced a readily reversible reduction of the sustained inward current (Fig. 6A) , as did tetracaine (Fig. 6B) , which is known to bind to a single, high affinity site within the lumen of the nAChR ion channel (38) . Proadifen, which preferentially binds to the desensitized state of the nAChR (39), was a potent inhibitor of the sustained current (Fig. 6C) , but in contrast to what was seen for QX-222 and tetracaine, inhibition by proadifen was not readily reversible with washing.
Structural Requirements for nAChR Activation-Two additional quaternary ammonium MTS reagents were used to further characterize the structural requirements necessary for nAChR activation (Fig. 7) . MTSMT, which is one methylene shorter than MTSET, adds a thio(trimethylamino)methyl group to Cys. MTSPT, which is one methylene longer than MTSET, adds homo-thiocholine. The consequence of MTSMT modification was qualitatively similar to that of MBTA and MTSEA. Exposure to 200 M MTSMT for 5 s resulted in irreversible inhibition of ␣Y93C, ␣Y198C, and ␥E57C mutant nAChRs, and there was no evidence that it reacted with ␥W55C. The result of MTSPT modification was qualitatively similar to that for MTSET. A 5-s treatment with 200 M MTSPT resulted in irreversible inhibition of ␣Y93C and ␥E57C mutant nAChRs, while for ␣Y198C, modification resulted in a prolonged, inward current ϳ1.4-fold greater in magnitude than the current elicited by 1 mM ACh.
To determine the maximal currents resulting from modification of ␣Y198C nAChRs by MTSET compared with MTSPT, oocytes expressing mutant nAChR were exposed sequentially to increasing concentrations of either reagent. For both MTSET and MTSPT, exposure to 0.1 M produced sustained inward currents, and for each reagent maximal currents were seen after exposure to concentrations of 1-3 M (Fig. 8, A and B) .
For ␣Y198C nAChRs, the maximal current produced by MT-SET was consistently ϳ5 times the response of MTSPT and ϳ10 times the response produced by 1 mM ACh. This difference might result either because MTSET reacted with more nAChRs or because after covalent modification it activated the ␣Y198C mutant nAChR in a more efficient manner than ACh or MTSPT. Fig. 8C shows that after an oocyte had been fully modified by MTSPT, treatment with MTSET caused no further increase in current, suggesting that the two reagents do react with the same pool of nAChRs.
Reaction Rate Constants-For the Cys mutants inhibited irreversibly by MBTA or MTS reagent, the rates of reaction with mutant nAChRs were determined by measuring the response to ACh after increasing reaction times and for different reagent concentrations (Fig. 9) . For the ␣Y198C mutant nAChR, the sustained currents resulting from exposure to MT-SET were measured as a function of reaction time (Fig. 9C) . The apparent bimolecular reaction rate constants (Table I) were determined from the rates of reaction, which increased with increasing reagent concentration. At each individual amino acid tested, the three MTS reagents reacted at similar rates. However, depending upon the amino acid, the reaction rate constants varied as much as 500-fold with the rank order k ␣Y198C Ͼ k ␣Y93C Ͼ k ␥E57C . At ␣Y198C the reaction rate constants (ϳ2.5 ϫ 10 5 M Ϫ1 s Ϫ1 ) were the same for MTSEA, which acted as an irreversible antagonist, as for MTSET and MTSPT, which acted as irreversible agonists. For the three reagents, k ␣Y198C was 40 -100-fold greater than k ␣Y93C and 200 -500-fold greater than k ␥E57C . For MBTA k ␥E57C was the same as for the MTS reagents, but MBTA reacted 10-and 100-fold more slowly than the MTS reagents at ␣Y93C and ␣Y198C, respectively. Rates of nAChR inactivation were not determined for MTSMT, the smallest compound, due to its instability in solution.
Reaction with BrACh-We also examined interactions of ␥E57C and ␣Y198C mutant nAChRs with BrACh, a sulfhydryl reactive agonist that acts as an irreversible agonist of wild type nAChR after reduction of the ␣Cys 192/193 disulfide (19, 20) . BrACh acted as a reversible agonist of wild type nAChR (K app ϭ 120 Ϯ 40 M, 4 oocytes) and elicited maximal responses about 50% that of ACh. As a reversible agonist, prolonged exposure to BrACh resulted in nAChR desensitization. After exposure to 1 mM BrACh for 5 s, even after a wash of several minutes, subsequent responses to ACh test pulses were reduced by ϳ15% compared with initial responses (data not shown). During a 3-min perfusion with 10 M BrACh, there was a sustained inward current similar in size to that seen upon transient application (Fig. 10A) . Upon washing, that current returned to base line, but even after a 2-min wash the response to an ACh test pulse was reduced by ϳ35% compared with control with little further recovery seen after longer washes. For ␥E57C mutant nAChR and 5-s exposure, BrACh acted as a reversible agonist (K app ϭ 90 Ϯ 40 M, 5 oocytes) producing a maximal current about 40% that of ACh. After exposure to 1 mM BrACh for 5 s, subsequent responses to ACh were within 90% of the pretreatment control (data not shown). Exposure of ␣Y198C nAChRs to 1 mM BrACh for 3 min resulted in a sustained inward current (Fig. 10B) . In contrast to what was observed for wild type nAChR, this sustained current persisted after washing, and it was partially inhibited by a 1 mM ACh test pulse. Application of 2 mM MTSET resulted in only a small increase of the sustained inward current. For the ␣Y198C mutant nAChR with application limited to 5 s, BrACh acted primarily as a reversible agonist (K app ϳ0.5 mM), similar in potency to ACh, with the maximal currents for BrACh ϳ30% that seen for ACh tested on the same oocyte (data not shown). However, upon washing after a 5-s exposure to 1 mM BrACh, the currents did not return completely to base line. Rather, there was a small sustained inward current ϳ15% of the peak BrACh response (Fig. 10C) . Repeated application of BrACh for 5-s intervals resulted in a decrease of the transient response associated with an increase of the sustained current to a value close to that seen for the initial maximal transient response. After a cumulative exposure to 1 mM BrACh for 25 s, subsequent reaction with 10 M MTSET resulted in a further increase of the sustained inward current, but only to a level about 50% of the initial ACh response. The small magnitude of this sustained current contrasts to the response of ␣Y198C nAChRs reacted with MTSET without prior exposure to BrACh, in which case the currents were 7-fold larger than the ACh response (Fig. 4) . These results indicated that BrACh did react covalently with ␣Y198C, and that when it did, it was a covalent agonist. However, the reaction rate constant for BrACh was ϳ5000-fold lower than that for MTSET, and the tethered acetylcholine was much less effective in gating the channel than tethered thiocholine at this position. ) were determined as described under "Experimental Procedures" and in Fig. 9 . The numbers in parentheses are the number of different oocytes used. B, current responses of an oocyte expressing ␣Y198C nAChRs exposed sequentially to: 1 mM ACh (5 s), 1 mM BrACh (3 min), 1 mM ACh (5 s), and 2 mM MTSET (5 s). C, after a 5-s test pulse of 1 mM ACh, an oocyte expressing ␣Y198C nAChRs was exposed to 1 mM BrACh for 5 s, followed by a 25-s wash, and this was then repeated four times. After exposure to BrACh for a total of 25 s, the oocyte was treated two times with 10 M MTSET.
Cys Scanning Mutagenesis in Agonist Site Loops A and D-
The previous experiments targeted amino acids known, from photolabeling and mutagenesis studies, to contribute to the agonist site. We then constructed additional mutant subunits containing single Cys substitutions at positions surrounding ␣Tyr 93 or ␥Trp 55 to identify other positions, which might show irreversible inhibition or activation after reaction with MBTA or the MTS reagents. The results of Cys scanning in loop A (␣90 -96) are summarized in Table II . Some Cys substitutions in this region did produce shifts in ACh K app . In contrast to the ␣Y93C mutation, with K app ϭ 520 M that was 20-fold weaker than that of wild type (K app ϭ 25 M), Cys substitutions ␣Ala 96 (K app ϭ 3 M) and ␣Asn 95 (K app ϭ 9 M) caused 10-and 3-fold leftward shifts in the ACh dose response. Cys substitution at the other positions resulted in less than 2-fold weakening of K app . Cys substitution at ␣Asn 94 did not alter K app , but the maximal currents were less than 1% of wild type and similar in magnitude to those seen for ␣Y93C. However, the decreased currents seen for the ␣N94C mutant were associated with dramatically lower levels of surface nAChR expression ( 125 I-␣-BgTx binding Ͻ10% of wild type; data not shown). The irreversible effects of MBTA, MTSEA, and MTSET were examined on these Cys mutants as described in Figs. 2 and 4. Other than ␣Y93C, the only residue in this region to show evidence of modification was ␣N94C. After reaction with 2 mM MTSEA for 5 s, ACh responses of the ␣N94C mutant nAChR were inhibited by 86%, and reaction with 100 M MT-SET for 5 s resulted in inhibition by 93%. However, reaction with 1 mM MBTA resulted in no inhibition greater than that seen for wild type (ϳ25%). Cys substitutions were also introduced at positions around ␥Trp 55 in loop D (␥52-58). For each of these substitutions, the K app for ACh was within a factor of 2 of wild type (data not shown), and the maximal currents were also similar to that seen for wild type nAChRs. As described previously, reaction of MBTA, MTSEA, or MTSET with ␥E57C resulted in irreversible inhibition of ACh responses. However, for each of the other mutants, ACh responses were unaltered. Thus, either the other positions tested were inaccessible to modification or the modification had no effect on ACh responses.
DISCUSSION
The use of Cys mutagenesis in conjunction with sulfhydryl reactive agonists and antagonists provides a method for investigating the agonist binding site that has yielded new structural information regarding the orientation of ligands bound within the site. Cys substitutions in loops A and C in the ␣-subunit and loop D of the ␥-subunit resulted in functional nAChRs and thus introduced reactive amino acid side chains at different positions within the agonist binding site. No ACh currents were detected for two of the mutants studied, ␣W149C and ␣Y190C. For the ␣W149C mutant, 125 I-␣-BgTx binding on the oocyte surface was similar to that seen for the ␣Y93C and ␣Y198C mutants, so the lack of ACh response did not result from a lack of surface nAChR. For ␣Y190C there was no detectable binding of 125 I-␣-BgTx on the oocyte surface, as was also seen for mutant mouse nAChR (28) , although the mouse mutant is expressed on the surface of HEK 293 cells (34 (20) . Our preliminary single-channel experiments showed that MTSET-activated ␣Y198C nAChRs have the same single-channel conductance as AChelicited wild type nAChRs (data not shown).
The persistent activation of the ␣Y198C nAChR by tethered thiocholine occurs for a nAChR without other mutations and with an unmodified structure of the ion channel. In contrast, the constitutively active receptor which results from replacement of ␣Trp 149 by an unnatural amino acid, Tyr-O-(CH 2 ) 3 N(CH 3 ) 3, is only seen when the mutant ␣-subunit is coexpressed with a mutant ␤-subunit (␤Leu 257 3 Ser) containing a substitution in the M2 ion channel domain that destabilizes the closed state and allows spontaneous channel opening in the absence of agonist (22) .
The sustained current response produced by MTSET treatment of oocytes expressing ␣Y198C nAChRs was consistently at least 5-fold greater in magnitude than ACh-elicited currents from the same oocytes. It is possible that introducing a Cys at residue ␣Tyr 198 changes the structure of the agonist binding site in such a way as to favor activation by agonists closer in structure to thiocholine than to ACh. To address this possibility, we examined the ability of several different agonists to activate the nAChR (data not shown). For wild type nAChR, current responses were not seen for choline (i.e. Ͻ0.5% of ACh maximum current), while tetramethylammonium was a weak agonist (K app ϳ2 mM) producing maximal currents about 1% that seen for ACh. For the ␣Y198C mutant, no responses were seen for choline, and responses were seen only for high concentrations of tetramethylammonium (30 -100 mM) that were Ͻ5% the magnitude of maximal ACh currents. Similarly, for the ␣Y198C mutant, the maximal response for pentyltrimethylammonium was Ͻ5% that for ACh. Thus, these limited observations provide no evidence that the ␣Y198C mutant is activated more effectively by simple alkyltrimethylammonium drugs than by ACh.
The reaction rate constants for the MTS reagents varied by more than 100-fold depending upon the position of the Cys substitution. For the three MTS reagents as well as MBTA, the reaction rate constant was highest for ␣Y198C, with the rate constants for the MTS reagents (k ␣Y198C ϳ2 ϫ 10 5 M Ϫ1 s Ϫ1 ) ϳ40-fold greater than for MBTA. The rate constants for reaction of MTS reagents at this position were 50 -100-fold higher than at ␣Y93C and 200 -400-fold higher than at ␥E57C. For MBTA the rate constants varied by only 10-fold. When rapidmixing techniques were used to study the reaction with ␤-mercaptoethanol, k ϳ6 ϫ 10 (31) . Further studies are required to determine whether the slow kinetics of solution exchange inherent in the perfusion of the oocyte results in an underestimation of the reaction rate constant of the MTS reagents at ␣Y198C. However, perfusion rate will not explain their lower rate constants for ␣Y93C and ␥E57C.
While ␣Y198C was identified as the most reactive of the positions examined within the ACh binding site, ␣Y93C and ␥E57C were also accessible for modification. It is striking that the reaction rate constants varied least for MBTA, the largest ligand studied. Although MBTA might be expected to bind with a preferred orientation within the ACh site, the similarity of the rate constants at the three positions provides no indication that this occurs.
The results presented here concerning the selective activation of the nAChR after modification of ␣Y198C, in conjunction with activation of nAChRs after modification of ␣Cys 192/193 with BrACh, emphasize that activation depends upon interactions of the acetyl end of ACh with amino acids in loop C. These studies provide no indication of the regions of the agonist binding site interacting with the positively charged trimethylammonio group during channel gating. Mutational analyses have identified tyrosines in loops A and C (34, 35) as well as anionic side chains in loops B, C, and F (43) as potential candidates (see, however, Ref. 44) . Incorporation of an unnatural amino acid at ␣Trp 149 suggests that interactions of the trimethylammonio group with the indole side chain of ␣Trp 149 may be important for gating (22) . [ 3 H]ACh mustard contains a positively charged quaternary aziridinium reactive group and labels ␣Tyr 93 , suggesting that at least in the desensitized state of the nAChR this position contributes to the cation-binding domain of the agonist-binding site (21) . Since the aziridinium Structures were modeled on a Silicon Graphics work station using Insight II version 98 (Molecular Simulations, Inc.) and were energyminimized using the Discover module. For ACh the extended length is indicated. For BrACh and MBTA, the dimension indicated is the distance from the surface of the quaternary ammonium to the carbon reacting with the sulfur, while for the MTS reagents it is the distance to the sulfoxide sulfur.
ion reacts efficiently with sulfhydryls, analysis of the interactions of ACh mustard with mutant nAChRs containing ACh site Cys substitutions should provide an alternative experimental approach to identify binding site groups interacting with the positive charge of ACh.
